• Publications
  • Influence
Revised response criteria for malignant lymphoma.
TLDR
New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma. Expand
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
TLDR
DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators. Expand
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
TLDR
The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with a better outcome in anaplastic large-cell lymphoma, ALK positive. Expand
Stromal gene signatures in large-B-cell lymphomas.
TLDR
Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP. Expand
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
TLDR
The selective development of ibrutinib for the treatment of ABC DLBCL is supported, with the highest number of responses occurred in ABC tumors that lacked BCR mutations, suggesting that oncogenic BCR signaling in ABC does not require B CR mutations and might be initiated by non-genetic mechanisms. Expand
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
TLDR
Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL. Expand
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
TLDR
Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkinymphoma cells. Expand
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
TLDR
The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis. Expand
Molecular diagnosis of Burkitt's lymphoma.
TLDR
Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma and the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens. Expand
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
TLDR
It is concluded that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma, however, the underlying features responsible for these differences remain to be defined. Expand
...
1
2
3
4
5
...